A study published in Alimentary Pharmacology Therapeutics in December 2017 compared the outcomes, pharmacokinetics, and immunogenicity of treatment intensification strategies in patients with Crohn disease (CD) who have lost clinical response to the anti–tumor necrosis factor (anti-TNF) therapy infliximab.
A study1 published in Alimentary Pharmacology Therapeutics in December 2017 compared the outcomes, pharmacokinetics, and immunogenicity of treatment intensification strategies in patients with Crohn disease (CD) who have lost clinical response to the anti—tumor necrosis factor (anti-TNF) therapy infliximab.
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab trough concentrations and loss of response. The authors note that infliximab treatment intensification is effective for most patients with Crohn disease (CD) to restore response, however.
The researchers conducted a retrospective cohort study comprising 103 patients with CD who had a loss of response during infliximab maintenance therapy, and who subsequently received a double dose (10 mg/kg), and/or a shortened interval between infusions. Infliximab and ATI concentrations were measured in consecutive trough samples, just before (T0) and just after (T+1) treatment intensification.
Overall, 37% of the patients did not respond to dose intensification. Patients with ATIs above 282 ng/mL at T0 were significantly less likely to achieve T+1 therapeutic drug levels. Conversely, drug levels at the time of loss of response were less correlated with the outcome of the intervention.
In a linked editorial2, S. Ben-Horin, MD, sees these results as “underscoring once more the need to identify patients who will respond to dose optimization, while sparing this costly and potentially detrimental intervention from patients with low likelihood to respond.”
Ben-Horin also explains that the results of the study find that dose doubling is more effective in restoring a drug level of greater than 3 mcg/mL compared with interval shortening. Although the exact interval of dose shortening was not reported within the study, it could stand to reason that some patients may have had received an “every 6-week shortening” rather than interval halving, the latter of which the paper notes is comparable to dose doubling.
“Nonetheless, these data are in line with prior observations on overall non-inferiority of dose-doubling [versus] interval halving, and together they support double dosing over interval-shortening as a viable option which may save patients the need for another infusion visit and contribute to improved quality of life,” writes Ben-Horin.
The best strategy may ultimately be the prevention of loss of response by utilizing a proactive approach with drug and ATI measurements, among other factors.
“Data such as presented by Dreesen and colleagues are important for advancing our knowledge of how to implement pragmatic, yet rational-based approach to patients with [loss of response] to anti-TNFs.”
References
1. Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. Published online December 11, 2017. Aliment Pharmacol Ther. doi: 10.1111/apt.14452.
2. Ben-Horin S. Editorial: restoring therapeutic infliximab drug levels in patients with loss of response- pharmacokinetics and anti-drug antibodies as useful guidance tools. Published February 18, 2018. Aliment Pharmacol Ther. 2018. doi: 10.1111/apt.14489.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).